08:37 AM EDT, 10/31/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) reported a Q3 non-GAAP net loss Thursday of $0.50 per diluted share, swinging from non-GAAP net income of $1.74 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.39.

Revenue for the quarter ended Sept. 30 was $500.9 million, down from $750.5 million a year earlier.

Analysts surveyed by Capital IQ expected $527 million.

The company's shares were down 2% in recent Thursday premarket activity.

Price: 276.00, Change: -5.49, Percent Change: -1.95